The Cell & Gene Therapy (CGT) industry has entered a new phase of healthcare transformation.
With 1,300+ companies, thousands of active development programs, growing clinical trials, increasing investment activity, and billions of dollars flowing into advanced therapies; the market opportunity is massive.
But for pharma leaders, investors, biotech companies, and healthcare strategists, the biggest challenge is:
-
Which companies have the strongest pipelines?
-
Which companies are truly innovating?
-
Which players have the highest clinical success potential?
-
Who has global manufacturing and commercialization strength?
Our Cell & Gene Therapy Intelligence Dashboard helps decision-makers answer these questions through a single platform; combining company intelligence, pipeline analysis, competitive benchmarking, manufacturing insights, investment activity, and strategic market data.
Track 1,300+ Cell & Gene Therapy Companies & Programs
Our dashboard provides complete visibility into the global CGT ecosystem.
Users can track:
-
1,300+ CGT companies globally
-
Clinical-stage biotech companies
-
Commercial-stage therapy developers
-
Gene editing companies • CAR-T therapy developers
-
Viral vector companies
-
Cell therapy innovators
Analyze:
- Pipeline portfolio
-
Therapy areas
-
Clinical development stage
-
Technology platforms
-
Regulatory progress
-
Strategic initiatives
-
Market positioning
The platform helps identify which companies are building the future of advanced medicine.
Leading CGT Companies Analysis
| Company | CGT Focus | Key Products | Pipeline Strength Score | Innovation Score | Clinical Success Score | Geographic Reach |
|---|---|---|---|---|---|---|
| Novartis | CAR-T Cell Therapy | Kymriah | 95/100 | 90/100 | 92/100 | Global presence across North America, Europe, and Asia-Pacific |
| Bristol Myers Squibb (BMS) | CAR-T Oncology Therapies | Abecma, Breyanzi | 93/100 | 88/100 | 94/100 | Global operations with strong presence in major healthcare markets |
| Vertex Pharmaceuticals | Gene Editing & Genetic Medicine | Casgevy | 91/100 | 98/100 | 95/100 | Expanding global presence through genetic medicine programs |
| CRISPR Therapeutics | CRISPR Gene Editing | CRISPR Platform Technologies, Gene-Editing Therapies | 90/100 | 100/100 | 92/100 | Presence across North America and global partnership networks |
| Regeneron Pharmaceuticals | Genetic Medicine Platforms | Genetic Medicine Programs | 89/100 | 93/100 | 90/100 | Strong global research and biotechnology presence |
Top Cell & Gene Therapy Companies Intelligence
The dashboard provides detailed benchmarking of leading CGT companies based on:
1. Pipeline Strength Score
Pipeline strength evaluates:
-
Number of active CGT programs
-
Clinical maturity
-
Phase advancement
-
Therapeutic diversity
-
Commercial potential
Companies with strong pipeline positioning include:
Pipeline Strength Score
Measures:
-
Number of active programs
-
Clinical-stage assets
-
Phase advancement
-
Therapeutic diversity
-
Commercial potential
Innovation Score
Measures:
-
Technology differentiation
-
Research capability
-
Platform strength
-
Novel therapeutic approaches
Clinical Success Rate
Measures:
-
Trial progression
-
Regulatory approvals
-
Commercialization ability
Geographic Reach Score
Measures:
-
Global clinical trials
-
Manufacturing presence
-
Market expansion capability
Request a Demo: https://www.towardshealthcare.com/cell-gene-intelligence-platform
Manufacturing & CDMO Intelligence
Cell & Gene Therapy success depends not only on scientific innovation and strong pipelines, but also on the ability to manufacture therapies at scale with reliable quality, regulatory compliance, and global capacity.
Our dashboard provides complete visibility into CGT manufacturing infrastructure, helping decision-makers understand where capacity exists, which companies are expanding, and how competitive manufacturing capabilities are evolving.
The dashboard tracks:
Viral Vector Manufacturing Capacity
-
Monitor critical manufacturing capabilities including:
-
AAV (Adeno-Associated Virus) manufacturing capacity
-
Lentiviral vector production capabilities
-
GMP-certified manufacturing facilities
-
Facility expansions and capacity growth
| Company | CGT Role | Key Areas Tracked | Manufacturing Capability Score |
|---|---|---|---|
| Lonza | Global CGT CDMO providing manufacturing support for cell and gene therapies. | • Manufacturing facilities • Cell & gene therapy capabilities • Facility expansion • CDMO activities |
95/100 |
| Catalent | Supports CGT companies with viral vector and gene therapy manufacturing solutions. | • Viral vector production • GMP facilities • Clinical manufacturing support • Commercial production |
90/100 |
| Thermo Fisher Scientific | Provides manufacturing and technology solutions for the CGT ecosystem. | • Bioprocessing solutions • Cell therapy support • Global manufacturing presence • Advanced therapy services |
94/100 |
From pharma innovations to competitive movements, track everything in one intelligent dashboard built for decision makers, Access the dashboard: https://www.towardshealthcare.com/access-dashboard
Funding, M&A, Licensing & Partnership Intelligence
The CGT market is heavily influenced by strategic investments, acquisitions, collaborations, and technology partnerships.
Our dashboard tracks major business activities shaping the future of the industry.
Track:
-
Funding rounds
-
Venture capital investments
-
M&A activities
-
Licensing agreements
-
Strategic partnerships
-
Company collaborations
ElevateBio
ElevateBio focuses on building an integrated cell and gene therapy ecosystem by providing enabling technologies, manufacturing capabilities, and platform solutions for CGT developers.
The dashboard tracks:
-
Funding growth
-
Platform expansion
-
Strategic partnerships
-
Market positioning
Investment Activity Score: 92/100 Strategic Partnership Score: 90/100
With complete intelligence covering companies, pipelines, clinical trials, manufacturing, investments, and competitive strategies, the CGT Dashboard enables faster and more informed healthcare decisions.
Quick Contacts
Complete Cell & Gene Therapy intelligence; from discovery to commercialization available in one platform. For quick call contact us at:
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04